Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information




Grenzacherstrasse 124
Basel, CH-4070, CHE


Head of Roche Venture Fund
Investment Director
Investment Director
Investment Director


Roche Venture Fund

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies.

Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent of collaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.

The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Recent Milestones


Company Date Round Size Participants
Alios BioPharma 4/2014Series B$41M4
MISSION Therapeutics 11/2013Series B£20M4
Aileron Therapeutics 11/2013Series E$30M6
Biodesy 10/2013Series A$15M3
Opsona 10/2013Series C€3M9
Horizon Discovery 6/2013Series C£6.9M11
Opsona 4/2013Series C€33M8
MacuLogix 3/2013Series A$3.6M4
Aileron Therapeutics 1/2013Series D$12M6
Epic Sciences 11/2012Series B$13M3
Ambit Biosciences 11/2012Venture Round$50M9
Foundation Medicine 9/2012Series B$42.5M7
Horizon Discovery 1/2012Series C$18.6M3
Curetis 10/2011Series A€9.6M2
MISSION Therapeutics 8/2011Venture Round$10M4
Ambit Biosciences 6/2011Series D$30M10
Conatus Pharmaceuticals 2/2011Series B$20M6
Horizon Discovery 9/2010Series C$9.8M4
CytomX Therapeutics 9/2010Series B$30M2
Nereus Pharmaceuticals 6/2010Series E$20M7
Cellerix 1/2010Series C$37.7M6
Cellerix 11/2009Series B€27M6
Opsona 6/2009Series B$4.6M6
Aileron Therapeutics 6/2009Series D$40M6
Alios BioPharma 6/2009Series A$8M3
Alios BioPharma 2/2009Series A$24M3
Intradigm Corporation 1/2009Series B$21.4M8
Inimex Pharmaceuticals 6/2008Series B$22M8



  1. Alios BioPharma Completes $41M Series B Financing ( [edit]
  2. Imperial Innovations Group plc : MISSION Therapeutics receives £20m Series B funding ( [edit]
  3. Aileron Therapeutics Secures $30M in Series E Equity Financing ( [edit]
  4. Biodesy Secures $15M in Series A Financing ( [edit]
  5. Opsona Therapeutics Raises €3M Series C Equity Financing ( [edit]
  6. Horizon Discovery Announces £6.9 Million ($10.5 Million) Series C Continuation Fundraising ( [edit]
  7. Opsona Therapeutics Raises €33M in Series C Financing ( [edit]
  8. MacuLogix Raises $3.6 Million in Series A Round ( [edit]
  9. Aileron Therapeutics Raises $12M in Series D Financing ( [edit]
  10. Epic Sciences Completes $13M Series B Equity Financing ( [edit]
  11. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia ( [edit]
  12. Foundation Medicine Closes $42.5M Series B Funding ( [edit]
  13. Horizon Discovery, Ltd.: Series C $18.6M ( [edit]
  14. Series A financing round expended to 34.1 euro ( [edit]
  15. MissionTherapeutics Ltd Raises $10 Million, Eyes Rapid Growth ( [edit]
  17. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing ( [edit]
  18. Horizon Discovery Raises $9.8M For Genetic Modeling ( [edit]
  19. CytomX Therapeutics Completes $30M Series B Financing ( [edit]
  20. Nereus Pharmaceuticals, Inc.: Series E $20M ( [edit]
  21. Cellerix, SL: Series C $37.7M ( [edit]
  22. Cellerix closes €27,2m financing round to bring product Cx401 to market ( [edit]
  23. Opsona Therapeutics, Ltd.: Series B $4.6M ( [edit]
  24. Aileron Therapeutics Closes Series D Financing ( [edit]
  25. Alios raises another $8M ( [edit]
  26. Alios BioPharma, Inc. Completes First Closing of Series A Financing with Commitment of $24 MM from 3 ( [edit]
  27. Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive ( [edit]
  28. Capital Funding Report [edit]
Edit This Page
Last Edited 4/7/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy